BACKGROUND: Advanced @entity978 ( @entity978 ) is curable by conventional chemotherapy in 60--70% of @entity1 . The pretreatment identification of a sizeable subgroup of @entity1 with sufficiently low @entity177 ( @entity177 ) to be eligible for investigational treatment is necessary. OBJECTIVES: To determine the prognostic significance of the number of involved sites (NIS) in @entity1 with advanced @entity978 and its relationship to the @entity3538 ( @entity3538 ). METHODS: A retrospective review of @entity1 with advanced @entity978 , defined as Ann Arbor stage (AAS) IB, IIB, III or IV, treated with @entity4349 -based regimens. The end-point was @entity177 . RESULTS: We identified 277 @entity1 with a median age of 32 yr (14--78), 57% of whom were males. AAS was I in 4% of @entity1 , II in 29%, III in 38% and IV in 29%. @entity1109 were recorded in 81%. Most @entity1 had @entity4383 (64%) and mixed cellularity (26%) histology. @entity3538 was greater-than-or-equals 3 in 44% of 242 evaluable @entity1 . The NIS was greater-than-or-equals 5 in 32% of the @entity1 and 20% of all @entity1 had both greater-than-or-equals 5 involved sites and @entity3538 greater-than-or-equals 3. The 10-yr @entity177 was 67%, being 76% vs. 50% for @entity1 with less-than-or-equals 4 vs. greater-than-or-equals 5 involved sites (P < 0.0001). The NIS (greater-than-or-equal 5), AAS IV and @entity417 were independent predictors of @entity177 in multivariate analysis. The NIS remained significant along with @entity3538 , when the latter was included in the analysis. @entity1 with greater-than-or-equals 5 involved sites and @entity3538 greater-than-or-equals 3 had 10-yr @entity177 overall, and relapse-free survival of 41%, 45% and 49%, respectively. CONCLUSIONS: The NIS was associated with @entity177 in advanced @entity978 , was independent of @entity3538 , and led to the identification of a sizeable subgroup of @entity1 with 10-yr @entity177 of approximately 40%. This factor should be evaluated during the development of prognostic systems.

Prognostic factors in advanced stage XXXX : the significance of the number of involved anatomic sites.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline'] @entity3538 :: ('MESH:D002341', 'Disease') :: ['IPS', 'International Prognostic Score'] @entity1109 :: ('MESH:D012678', 'Disease') :: ['B-symptoms'] @entity177 :: ('MESH:D051437', 'Disease') :: ['FFS', 'failure-free survival'] @entity4383 :: ('MESH:D020518', 'Disease') :: ['nodular sclerosis'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', "Hodgkin's lymphoma"]
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin's lymphoma']
